Purity test of Epirubicin Hydrochloride

Significance of the topic

Residual solvent analysis in pharmaceutical compounds ensures drug safety by detecting organic impurities that may harm patients.

Objectives and overview of the study

The goal was to evaluate residual solvents in epirubicin hydrochloride using Japanese Pharmacopoeia guidelines.

• Quantification of acetone, methanol, ethanol, 1-propanol and 1,4-dioxane.
• Validation of chromatographic performance on a highly inert GC column.

Methodology and instrumentation

The analytes were separated by gas chromatography with flame ionization detection on an InertCap Pure-WAX capillary column (0.53 mm I.D. × 30 m, 1 μm). Temperature program: 40 °C (11 min), ramp 10 °C/min to 90 °C, ramp 50 °C/min to 130 °C (30 min). Carrier gas: helium at 20 kPa. Injection: split 1:15 at 120 °C.

Used Instrumentation:

• GC system with FID.
• InertCap Pure-WAX column, GL Sciences.
• Internal standard: 1,4-dioxane.

Main results and discussion

All solvents were baseline resolved with good peak shape and inertness. The resolution between the first analyte and internal standard exceeded the JP15 requirement (R > 30). Calibration levels ranged from 0.0068 to 1.25 μL/mL and produced linear responses.

Benefits and practical applications of the method

• Reliable detection of trace residual solvents according to pharmacopeial standards.
• High column inertness reducing active site interactions, improving sensitivity.
• Applicable to quality control in manufacturing of epirubicin hydrochloride and similar cytotoxic compounds.

Future trends and possibilities for use

Advances may include coupling to mass spectrometry for lower detection limits and broader solvent panels, automated sample preparation and green solvent methods to minimize environmental impact.

Conclusion

The study demonstrates a robust GC-FID method using an inert capillary column to quantify residual solvents in epirubicin hydrochloride meeting Japanese Pharmacopoeia requirements, offering a reliable tool for pharmaceutical quality control.

Reference

No external references were provided in the source document.